Contrave was approved in September 2014 as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI ≥30 or ≥27 in the presence of at least one weight-related comorbid condition.
Contrave combines naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine.
ome studies suggest naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system).
However, the exact neurochemical effects of Contrave resulting in weight loss are not fully understood.
Contrave is available in 8 mg/90 mg extended-release tablets in 120-count bottles.
For more information call (877) 825-3327 or visit Contrave.com.
This article originally appeared on MPR